Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

International Collaboration Finds Three New Lupus Genes

By BiotechDaily International staff writers
Posted on 11 Apr 2012
Three newly confirmed lupus genes are providing new clues into this devastating autoimmune disorder.

An article published in the April 6, 2012, issue of the American Journal of Human Genetics described three lupus genes discovered by scientists from Oklahoma Medical Research Foundation (OMRF; Oklahoma City, OK, USA). The massive international collaboration included universities and research facilities in Granada (Spain), Taipei (Taiwan), Seoul (republic of Korea), Bogota (Colombia), and across the United States, OMRF scientists collected more than 17,000 samples for large-scale genetic testing.

The project, which started in 2009, took one year to gather the samples and another year to run the genetic tests. Since then, the researchers have studied the data, according to lead author and OMRF scientist Christopher Lessard, PhD “We have pinned down three new genes that show statistical significance for lupus risk,” he said. “We’ve also turned up another 11 regions we think might be related to lupus, but those need more study.”

The study is significant for its inclusion of several ethnic groups and findings that show that the genes that cause lupus are not always universal, according to OMRF researcher Patrick Gaffney, MD Utilizing samples from a wide range of ethnic backgrounds, scientists found the genes IRF8 and TMEM39a were associated with lupus in European-American, African-American, Gullah, and Asian patients. A third gene named IKZF3 was only significant in African-American and European-American samples.

The huge undertaking has already revealed other discoveries, according to Dr. Gaffney. Up to now, the project has culminated in at least 15 published articles and several more are in the pipeline. The next step will be studying the genes to find out what role they play in lupus, according to Dr. Lessard.

“Identifying and characterizing these genetic risk factors in lupus will undoubtedly lead to improved diagnostics and therapeutics for this complex disease," said senior author and OMRF scientist Kathy Moser, PhD.

Lupus Foundation of America, Oklahoma chapter executive director Mannix Barnes noted that the finding marks another significant step for patients. “The importance of continued research for lupus is imperative to finding the cause and treatments for a disease that affects over 1.5 million Americans, mostly women,” said Dr. Barnes. “I can honestly say from an executive viewpoint in an organization that fields thousands of calls annually from women affected by this disease, I hope research one day will be able to put us out of business and start saving lives in return.”

Related Links:

Oklahoma Medical Research Foundation



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.